SciSparc & Clearmind Patent for Binge Behavior Treatment in Mexico
Ticker: SPRC · Form: 6-K · Filed: Feb 4, 2025 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Feb 4, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, collaboration, pharmaceuticals, mexico
Related Tickers: SPRC
TL;DR
SciSparc & Clearmind just got a patent in Mexico for a combo drug to treat binge behavior. Big win!
AI Summary
On February 4, 2025, SciSparc Ltd. announced a collaboration with Clearmind that resulted in the publication of a patent for a binge behavior combination treatment in Mexico. This patent covers the use of SciSparc's cannabinoid-based drug, SCI-110, in combination with Clearmind's psychedelic drug, CMND-100, for treating binge behavior.
Why It Matters
This patent publication in Mexico could pave the way for new therapeutic options for binge behavior disorders, potentially expanding SciSparc's and Clearmind's market reach.
Risk Assessment
Risk Level: medium — The filing is a routine report of a patent publication, but the success of the drug combination and its market adoption remain subject to regulatory approvals and clinical outcomes.
Key Players & Entities
- SciSparc Ltd. (company) — Registrant
- Clearmind (company) — Collaborator
- SCI-110 (drug) — SciSparc's cannabinoid-based drug
- CMND-100 (drug) — Clearmind's psychedelic drug
- February 4, 2025 (date) — Date of press release
- Mexico (location) — Jurisdiction of patent publication
FAQ
What is the specific nature of the binge behavior that this patented treatment aims to address?
The filing does not specify the exact types of binge behavior, but it refers to a 'binge behaviour combination treatment'.
What is the current development stage of the combination treatment involving SCI-110 and CMND-100?
The filing indicates the publication of a patent for the combination treatment, suggesting it has moved beyond initial research but does not specify further development stages.
Are there any immediate commercialization plans for this patented treatment in Mexico?
The filing does not detail immediate commercialization plans, focusing on the patent publication as a significant step.
What is the relationship between SciSparc Ltd. and Clearmind?
SciSparc Ltd. and Clearmind are collaborators on the development of a combination treatment for binge behavior, as evidenced by their joint patent publication.
Does this patent publication imply regulatory approval for the treatment in Mexico?
No, a patent publication is distinct from regulatory approval. The filing only states that a patent has been published, not that the treatment is approved for use.
Filing Stats: 307 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2025-02-04 16:01:06
Filing Documents
- ea0229818-6k_scisparc.htm (6-K) — 12KB
- ea022981801ex99-1_scisparc.htm (EX-99.1) — 7KB
- 0001213900-25-010064.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: February 4, 2025 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3